home / stock / evotf / evotf news


EVOTF News and Press, Evotec Ag Ord From 12/19/23

Stock Information

Company Name: Evotec Ag Ord
Stock Symbol: EVOTF
Market: OTC
Website: evotec.com

Menu

EVOTF EVOTF Quote EVOTF Short EVOTF News EVOTF Articles EVOTF Message Board
Get EVOTF Alerts

News, Short Squeeze, Breakout and More Instantly...

EVOTF - Evotec receives US$ 2.5 M Grant to Leverage Human iPSC-Derived Teratogenicity Platform for Global Health Programmes

EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY ("GHDC") AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC'S IPSC-DERIVED HIGH-T...

EVOTF - Evotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune Diseases

GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF ANCA-ASSOCIATED VASCULITIS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN WILL COLLECT BIOSAMPLES FROM ANCA-ASSOCIATED VASCULITIS PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PA...

EVOTF - Evotec-partner Jingxin Receives Approval for EVT201 in China

EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ("NMPA") AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA EVOTEC'S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD ("JINGXIN") WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA HAMBURG, GE...

EVOTF - Evotec Presents Precision Medicine Platforms for Accelerated Pipeline Building at Capital Markets Day

PRECISION MEDICINE CAPABILITIES SHAPING (NEW) MARKETS WITH FIRST-IN-CLASS THERAPEUTICS PANOMICS, IPSC & A.I./M.L. PLATFORMS ARE THE STEP CHANGE FOR GROWTH AND ACCELERATED PIPELINE BUILDING CONFIRMATION OF ACTION PLAN 2025 GOALS AND PROGRESS UPDATE HAMBURG, GERMANY / ACCESSWIRE ...

EVOTF - Evotec SE (EVO) Q3 2023 Earnings Call Transcript

2023-11-11 13:31:03 ET Evotec SE (EVO) Q3 2023 Earnings Conference Call November 8, 2023, 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johns...

EVOTF - Evotec SE Reports Results for the First Nine Months 2023 and Provides Corporate Update

CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS PIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATION ALL ELEMENTS OF GUIDANCE CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / November 8, 2023 / Evotec SE (Frankf...

EVOTF - Evotec and Dewpoint Therapeutics Enter Strategic Partnership in Oncology

STRATEGIC PARTNERSHIP TO ACCELERATE DEWPOINT'S LEADING ONCOLOGY PIPELINE PROGRAMMES TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC'S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORM AGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILES...

EVOTF - Portfolio Update: Next Trades

2023-11-05 12:17:29 ET Summary The UST yield curve has steepened and this could provide an opportunity to buy US banking stocks on weakness in a no-recession scenario. Japan and Eurozone exporters can benefit from a global downturn due to easier central bank policies depreciating ...

EVOTF - Evotec SE to announce results for the first nine months 2023 on 08 November 2023

Evotec SE / Key word(s): Miscellaneous Evotec SE to announce results for the first nine months 2023 on 08 November 2023 01.11.2023 / 12:05 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 01 November 2023: Evotec SE (Frankfurt Stock Exch...

EVOTF - Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'

A UNIQUE COMPANY CREATION VEHICLE INITIATED BY LIGHTSTONE VENTURES AND EVOTEC SE, AND ESTABLISHED WITH PARTNERS CLAVYSTBIO, LEAPS BY BAYER, POLARIS PARTNERS, AND THE POLARIS INNOVATION FUND FIRST-OF-ITS-KIND PARTNERSHIP IN SINGAPORE AND ASIA LEVERAGES BREAKTHROUGH SCIENCE FROM RESEARCHERS AT...

Previous 10 Next 10